If you're leading a late-stage medical technology company with proven science and need capital to commercialize, send us a brief.
Your brief should include:
· Company name and technology description (2-3 paragraphs)
· Development stage and regulatory pathway
· Clinical data summary or proof of concept results
· Intellectual property status (patents issued, applications pending)
· Previous funding sources and amounts (grants, seed, philanthropy)
· Capital requirement and specific use of proceeds
· Management team background and relevant experience
· Timeline to commercial launch with proper funding
· Why you believe Méridian is the right partner
We review all briefs within 5 business days. If there's potential alignment, we'll schedule an in-person meeting to discuss your technology in depth and evaluate whether we're the right fit.
If you're an institutional investor or family office interested in healthcare companies at the critical inflection point—past grants and seed funding, before commercial launch—reach out to discuss access to our deal flow.
Our investor network receives:
· Comprehensive due diligence reports on late-stage companies
· Direct introductions to management teams for qualified opportunities
· Investment opportunities that match specific criteria
· Strategic insights on healthcare capital markets
To discuss investor access, please provide:
· Investment firm or family office name
· Current healthcare portfolio and investment focus
· Typical investment size and stage preference
· Geographic or therapeutic area focus
· Contact information for appropriate investment team member
2020 Main St, Suite 1225, Irvine, CA 92614, USA
Phone +1 (310) 927-0159 Email: ben@benlapointe.com
Méridian Strategic Advisors, Inc.
2020 Main Street, Suite 1225, Irvine, CA 92614
(310) 927-0159 ben@benlapointe.com
© 2026 Méridian Strategic Advisors. All rights reserved.